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Transmission of HIV strains with drug-resistance mutations (DRMs) causes public health problems in
resource-rich countries. We use a stochastic model, with data from viral competition experiments, to
analyze the effect of fitness costs (FCs) and genetic bottlenecks on limiting transmission of 10 clinically
significantDRMs.TransmissionofDRMswithlowFCs(,0.2%)issimilartowild-type;transmissionchains
last ,8 generations causing clusters of ,60 infected individuals. Genetic bottlenecks substantially limit
transmission of DRMs with moderately high FCs (,0.6%); chains last ,1–3 generations with transmission
clusters of 2–7. Transmission of DRMs with extremely high FCs (.6%) only occurs from ,5% of index
cases. DRMs can revert to wild-type and remain as minority strains, within treatment-naı ¨ve individuals,
undetectable by current resistance assays. We calculate, based on assay sensitivity, the length of time each
DRM is detectable within individuals. Taken together, our results imply a hidden epidemic of transmitted
resistance may exist.
A
widevarietyofHIVmutationsconferringresistancetoantiretroviralshaveevolvedoverthepast20years.
The presence of even a minority population of certain variants with drug resistant mutations (DRMs) to
HIVcanincreaseanindividual’sriskofvirologicfailureonfirst-linetherapyasmuchasthreefold
1–3.Viral
competition experimentshaveshownDRMsreducethereplication rate(i.e.,fitness)ofHIV;somehavealimited
effect on reducing fitness, whilst others have a substantial effect
4,5. Reduced fitness limits the transmission of
DRMs to some degree, because these mutations can revert to wild-type and wild-type strains can then out-
compete the strains with the DRM. Analysis of viral sequences in acutely infected individuals has shown that at
each transmission event a genetic bottleneck occurs and most HIV infections are initiated by a single variant
6,7.
Duetothisfoundereffect,individualsinfectedwithbothwild-typeandresistantstrainsareonlylikelytotransmit
one strain. Hence, genetic bottlenecks could also limit transmission of DRMs. Here, we use data from viral
competition experiments and a novel stochastic model to evaluate the effect of fitness costs and genetic bottle-
necks on limiting transmission of 10 isogenic strains of HIV with DRMs. For comparative purposes, we also
model the transmission of the corresponding wild-type strain. Each of the 10 DRMs that we investigate (Y181C,
K103N,K70R,L74V,K219Q,M41L,D67N,T215Y,M184VandK65R)isasinglepointmutationassociatedwith
resistance to nucleoside or non-nucleoside reverse transcriptase inhibitors. They range from those with a very
high fitness cost to those with a very low fitness cost
4. Our modeling study is the first to investigate the impact of
relativefitnessandgeneticbottlenecksonlimitingtransmissionofDRMs.Thestochasticmodelwepresentinthis
studycanbeusedtoassesstransmissionbetweenMenWhoHaveSexWithMen(MSM)orheterosexuals;herewe
parameterize it to reflect transmission in a MSM community in a resource-rich country.
All of the DRMs we investigate are of clinical significance
8. For example, M184V reduces susceptibility to
emtricitabine (FTC) and lamivudine (3TC) by .100-fold and K65R is the primary mutation associated with
resistance to tenofovir (TFV)
9,10. We measure transmission in terms of the length of transmission chains and the
sizeofthetransmissionclustersthateachstraincangenerate.Forwild-typestrainsofHIV,wedefinethelengthof
atransmissionchaintobethenumberofgenerationsofindividualsthataredirectly,orindirectly,infectedbythe
indexcase;wheretheindexcaserepresentsthefirstgeneration.Wedefinethesizeoftheatransmissionclusteras
the index case plus the total number of individuals who are directly, or indirectly, infected by the index case over
the duration of the transmission chain. Definitions of transmission chains and transmission clusters for strains
with DRMs are not as simple as for wild-type strains. DRMs in untreated individuals can revert to wild-type by
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SCIENTIFIC REPORTS | 2 : 320 | DOI: 10.1038/srep00320 1back-mutation, then decrease in the plasma relative to the wild-type
strain and subsequently not survive a genetic bottleneck. At that
point the DRM would no longer be transmitted and its transmission
chain will terminate. For each of the 10 strains with DRMs that we
investigate, only one nucleotide change is necessary for the resistant
strain to revert to wild-type. In the case of a strain with the T215Y
mutation, a single nucleotide change results in a unique set of wild-
type viruses that fully restore replication capacity and drug suscept-
ibility
11,12. For a strain with a DRM we define the length of a trans-
mission chain to be the number of generations of HIV-infected
individuals that receive the DRM directly, or indirectly, from the
index case; where the index case represents the first generation.
We define the size of a transmission cluster as the index case plus
the total number of HIV-infected individuals that receive the DRM
directly, or indirectly, from the index case over the duration of the
transmission chain.
Tobeginouranalysesweuseddatafromviralcompetition experi-
ments to estimate the relative fitness costs for each of the 10
isogenic strains with DRMs relative to the fitness of the correspond-
ingwild-typestrain;seeMethodsandCongetal.
4Wethendesigneda
stochastic mathematical model that includes the effect of relative
fitness costs and genetic bottlenecks on limiting transmission (see
Methods). We used this model to calculate the expected lengths of
transmission chains and the size of transmission clusters generated
by the wild-type strain and each of the 10 isogenic strains with
DRMs. To make our calculations we constructed a hierarchial mod-
elingframework.Specifically,wecoupledthestochasticmodelwitha
previously published within-host model
13 in order to track the viral
dynamics within each infected individual in a transmission chain.
For individuals infected with only wild-type strains the within-host
modelsimulatedthetemporaldynamicsoftheindividuals’viralload
over time until the individual was treated. For individuals initially
infectedbystrainswith aDRM,thewild-type strainevolvedthrough
back-mutationandthewithin-hostmodelsimulatedthecompetitive
dynamics between the wild-type strain and the strain with the DRM.
In each infected individual the proportion of the virion population
containing the DRM decreased over time; the rate of decrease was a
function of the relative fitness cost. Within-host viral dynamics for
each of the 10 DRMs were modeled using their estimated relative
fitness cost (see Methods).
We modeled the probability that an infected individual in the
transmission chain would transmit HIV at any point in time as
a stochastic process that was a time-dependent function of their
infectivity (we estimated their infectivity by using viral load data
simulated by the within-host model) and their sexual behavior.
Sexual behavior was modeled independently for each infected indi-
vidual using stochastic functions to determine their number of sex
acts, as well as the timing of these sex acts. Hence the number of
transmission events that occurred, and the timing of these events,
was determined probabilistically for each individual based on viro-
logic and behavioral factors. At each transmission event we modeled
a genetic bottleneck. Whether the founder virus was wild-type or a
strain with a DRM was determined probabilistically, but depended
upon the composition (at the time of the transmission event) of the
virion population in the transmitting individual (which was tracked
bythewithin-hostmodel).Forfurtherdetailsofthemodelingframe-
work see Methods.
The model was designed to reflect the stochastic development
of transmission chains and transmission clusters, which resulted
fromsexual transmission, incommunities ofmen whohave sexwith
men (MSM) in resource-rich countries. Since treatment is readily
available in these countries we assumed individuals would receive
first-line and, if necessary, second-line regimens. Effective treatment
reduces the viral load in HIV-infected individuals below 50 copies/
mL and once viral load falls below 400 copies/mL transmission has
beenfoundtobeextremelyunlikely
14;consequently,inourmodeling
we assumed the probability that treated individuals with undetect-
able viral load would transmit HIV would be negligible. Even in
resource-rich countries, individuals who become infected with
HIV are generally not treated until there has been significant decline
in CD4 cells, which does not generally occur for several years. We
estimated the time from infection to treatment initiation by using
datafromtheDepartmentofPublicHealthinSanFrancisco
15.Based
ontheseestimateswevariedtimetotreatmentfrom6to8yearswhen
modeling the stochastic development of transmission chains. See
Methods for details.
We also estimated the value of the Basic Reproduction Number
(R0) for each of the strains with a DRM (see Methods) by tracking
transmissionchains.Forboththewild-typeandresistantstrainsR0is
defined to be the average number of secondary infections resulting
fromanindexcaseinapopulationofentirelysusceptibleindividuals.
Individuals who are directly infected by the index case are defined
as secondary infections. When we model a transmission chain for a
DRM we begin with an index case initially infected with only a re-
sistant strain. During the course of their infection the resistant strain
canreverttowild-type.Hence,theindexcasecantransmitbothwild-
type and resistant strains. When calculating the value of R0 for a
DRMweincludeinourcalculationsonlyindividualswhoaredirectly
infected with resistant strains by the index case.
Even when a DRM is being transmitted, the presence of the DRM
may be undetectable in a treatment-naı ¨ve individual. The sooner
the strain is genotyped, after transmission occurs, the more likely
the DRM will be detected. However, whether or not a DRM is
detected will also depend upon its relative fitness cost and the sens-
itivityof theresistance assay. Ifreversion occurs, the wild-type strain
(due to its greater fitness) will begin to out-compete the strain with
the DRM
16,17. Hence, over time the DRM may eventually become
undetectable in a treatment-naı ¨ve individual. The lower the relative
fitness cost of the DRM and/or the more sensitive the assay (i.e., the
lower the detection threshold of the assay), the longer the DRM will
remain detectable
3,18. Currently, DRMs are only detected if they are
present in at least 20% of the virus population in the plasma of an
HIV-infected individual; this is the sensitivity of current resistance
assays which are based on sequence analysis
19. A new generation of
resistance assays, based on real-time PCR, is gradually being intro-
duced; currently, these assays serve only as research tools
20,21. These
assays are much more sensitive than the current resistance assays as
they have much lower detection thresholds
22. Therefore, the intro-
duction of these new assays will increase the detection of DRMs
23.
Detection thresholds of these new resistance assays differ by strain
(from 0.8% to 2%) based on the primers used in the assay, as well as
the frequency of naturally occurring polymorphisms in the region of
the DRM
22. We calculated detection times, in treatment-naı ¨ve indi-
viduals,foreachofthe10DRMs.Tomakethesecalculationsweused
our estimates of relative fitness costs and the within-host model of
viral dynamics
13 (see Methods). We calculated detection times based
on using current resistance assays with detection thresholds of 20%,
and also using next generation resistance assays with detection
thresholds of 1%.
Results
RelativeFitnessCostsofDRMs.Ourresultsshowthatthe10DRMs
that we investigated show considerable variation in their relative
fitness cost; ranges are given in Table 1. We note that we did not
estimate the relative fitness cost listed for M184V in Table 1. This is
because it had already been estimated by Paredes et al.
16. In our
analyses we used it as a calibration factor to calculate the relative
fitness costs for the other 9 DRMs (see Methods). Relative fitness
costsrangefromaminimumof0.11%forK70R(themostfitstrainin
our analysis) to a maximum of 16% for K65R (the least fit strain
in our analysis).
www.nature.com/scientificreports
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Supplementary Information (SI), show the competitive-reversion
dynamics within treatment-naı ¨ve HIV-infected individuals. The dy-
namics of the wild-type strain within an individual are shown by the
blue line and the dynamics of the strain with a DRM by the red data.
In these simulations the individual is assumed to be initially infected
withthestrainwiththeDRMandthewild-typestrainemergesdueto
back-mutation. Thebetweenstrain competitivedynamicsare shown
up until the time the individual receives treatment (Figure 1 and
Figure S1 in the SI). The maximum time to treatment is assumed
to be 8 years, as this is the maximum time to treatment initiation
we estimated from data from HIV-infected individuals in MSM
communities (see Methods). The horizontal black line in Figure 1
(and Figure S1 in the SI) delimits the 20% threshold at which DRMs
can no longer be detected by current resistance assays. In each
simulation the wild-type strain out-competes the strain with the
DRM because the wild-type strain has the highest viral replication
rate (i.e., the strain with the DRM is less fit); see Table 1.
Simulations are shown for K65R (Figure 1a), M184V (Figure 1b),
M41L (Figure 1c), L74V (Figure 1d), K219Q (Figure 1e) and K70R
(Figure 1f). Simulations for the remaining 4 DRMs (Y181C , T215Y,
D67N and K103N) are shown in Figure S1 in the SI, because their
dynamics are similar to DRMs shown in Figure 1. Specifically, the
dynamics of Y181C are similar to K70R, T215Y to M184V, and both
D67NandK103NaresimilartoM41L.Thehighertherelativefitness
cost of the DRM, the faster it is out-competed by the wild-type
strain and the shorter the detection time (Figure 1 and Figure S1 in
the SI, and Table 1). Our results show the detection times of trans-
Table 1 | TherelativefitnesscostofM184Vwaspreviouslycalculated
16,andusedasacalibrationfactortoestimatetherelativefitnesscosts
for the other 9 DRMS (see Methods). Ranges reflect heterogeneity in the data. Values (median and interquartile range (IQR)) for R0’s and
detection times were estimated using uncertainty analyses. The maximum detection time was 8 years, because individuals in resource-rich
countries are on treatment by then
DRM Relative fitness cost (%) R0 Median (IQR)
Detection Time (years) Assay
Sensitivity (20%) Median (IQR)
Assay Sensitivity (1%)
Median (IQR)
K70R 0.11–0.23 1.5 (1.5–1.6) .8 .8
Y181C 0.17–0.35 1.4 (1.3–1.5) 7.8 (6.8–8.0) .8
K219Q 0.40–0.80 0.74 (0.62–0.84) 3.7 (3.2–4.3) 5.3 (4.6–6.2)
L74V 0.57–1.2 0.51 (0.43–0.61) 2.7 (2.4–3.1) 3.8 (3.3–4.5)
D67N 1.1–2.1 0.27 (0.22–0.32) 1.5 (1.3–1.8) 2.1 (1.9–2.5)
M41L 1.2–2.5 0.21 (0.18–0.25) 1.3 (1.1–1.5) 1.8 (1.5–2.1)
K103N 1.7–3.5 0.14 (0.12–0.18) 0.97 (0.84–1.1) 1.3 (1.1–1.6)
T215Y 3.7–7.3 0.05 (0.04–0.06) 0.47 (0.40–0.56) 0.63 (0.55–0.75)
M184V 4.0–8.0
16 0.04 (0.04–0.05) 0.43 (0.37–0.52) 0.58 (0.50–0.70)
K65R 8.0–16 0.02 (0.02–0.04) 0.21 (0.17–0.25) 0.28 (0.23–0.33)
Figure 1 | Numerical results from the within-host model showing the fraction of virions that are resistant (red curve) as a function of years since
infection in a treatment-naı ¨ve individual. The blue curve indicates the fraction of virions that are wild-type. The 20% threshold for detection of
resistancebasedoncurrentresistanceassays,isdenotedbythedashedblackline.DRMsshownareK65R(a),M184V(b),M41L(c),L74V(d),K219Q(e),
K70R (f).
www.nature.com/scientificreports
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mostfitstraininouranalysis)toaminimumof,2monthsforK65R
(theleastfitstraininouranalysis).Based onour calculatedestimates
of relative fitness costs and detection times (based on the 20% detec-
tion threshold of the current resistance assays) we categorize the
DRMs into 4 fitness categories: (i) DRMs that have very low fitness
costs with detection times of ,8 years after transmission (K70R and
Y181C), (ii) DRMs that have moderate fitness costs with detection
times of ,3 to 4 years after transmission (K219Q and L74V), (iii)
DRMs that have high fitness costs with detection times of ,1 to 1.5
years after transmission (D67N, M41L and K103N), and (iv) DRMs
that have very high fitness costs with detection times of only ,2t o6
months after transmission (T215Y, M184V and K65R) (Figure 1,
Figure S1 in the SI, and Table 1; median and interquartile ranges
(IQRs) are shown).
Table 1 also shows the detection times of the DRMs if the
next generation resistant assays are used, assuming their detection
threshold is 1%. Relative fitness costs will be extremely important in
determining the effect of increasing assay sensitivity on increasing
the detection time (Table 1). Our results show that using the next
generation of resistance assays will not significantly increase the
detection time of transmitted DRMs with low fitness costs (K70R
and Y181C), because they can already be detected for up to ,8 years
when treatment has generally already been initiated. However, the
introduction of the new assays will increase the detection time for
transmitted DRMs that have moderate fitness costs (K219Q and
L74V)by,1yearandthedetectiontimefortransmittedDRMswith
highfitnesscosts(D67N,M41LandK103N)by,6months.Notably,
the introduction of the new assays will have very little effect on
increasing the detection time of transmitted DRMs with very high
fitness costs (T215Y, M184V and K65R). For example, the detection
time after the transmission of K65R will remain very low; it will only
increase from the current time of ,1 month to ,2.3 months.
EstimatesofR0:wild-typestrains&strainswithDRMs.Thevalues
of R0 for the strains with DRMs (Table 1) correspond to the four
fitness categories we defined based on their relative fitness costs and
detection times; median and IQRs for the R0’s for each of the DRMs
aregiveninTable1. Ourcalculations showthatDRMswithvery low
fitness costs (K70R and Y181C) have a R0 of ,1.4-1.6, very close to
the R0 of 1.6 for the wild-type strain. Since the R0’s for K70R and
Y181C are greater than one, the transmission of these DRMs could
reach self-sustaining levels. However, the R0 values for the DRMs
with a moderate fitness cost (K219Q and L74V) are less than one;
they range from 0.5 to 0.7. These results indicate the transmission of
K219Q or L74V is unlikely to be self-sustaining, but they would be
transmitted to some extent if they evolve under treatment pressure.
The values of R0 for the DRMs with a high fitness cost (D67N, M41L
andK103N)aremuchlowerthanone,rangingfrom0.1to0.3.These
results indicate that even if high levels of D67N, M41L or K103N
evolveundertreatmentpressuretheirtransmissionislikelytobelow.
DRMs that have very high fitness costs (T215Y, M184V and K65R)
haveextremelylowR0’s,rangingfrom0.02to0.05.Sincethesevalues
are close to zero these DRMs, in general, would only be infrequently
transmitted.
Transmission Chains & Clusters: wild-type strains & strains with
DRMs. The percentage of simulations where no transmission from
the index case occurred is given in Table 2; results are given for both
the wild-type strain and the 10 strains with DRMs. For each strain,
results are based on 10,000 realizations of the stochastic model; each
simulation was run for a maximum of 20 years. In order to predict
(for each DRM) the length of a transmission chain that would result
from a single mutation, we used the same number of realizations for
each of the 10 DRMs. This enabled us to eliminate the confounding
effect that would occur due to the differences in the mutation
frequency of each DRM in treated individuals. Mutation frequency
for each of the 10 DRMs is extremely variable, and depends on both
adherence and treatment regimens. For each of the 4 DRMs with the
lowestfitness costs,transmission occurred inover 5,300realizations.
For each of the remaining 6 DRMs, with higher fitness costs,
transmission occurred in at least 400 realizations. The standard
deviations (SDs) of the cluster sizes for these 6 DRMs ranges from
0.24 to 1.1 (see Table S1 in the SI). These SDs are small, all are
essentially less than one individual, indicating the sample size of
10,000 realizations is sufficient to describe the distributions.
A transmission chain that lasts for only one generation in-
dicates there is only direct transmission from the index case and
no subsequent transmission (i.e., only transmission from the first
generation to the second generation). A cluster size of two indicates
the index case only infects one individual, since the index case is
included when calculating cluster size. Transmission chains termin-
ate due to either stochastic effects or to reaching the cutoff of twenty
years.FigureS4intheSIshowscumulativedistributionfunctionsfor
the proportion of (non-null) transmission chains that terminated in
each year for each strain with a DRM, and the wild-type strain.
Strains with R0.1 generally terminated due to reaching the cutoff
of 20 years, while strains with R0,1 generally terminated (due to
stochastic effects) before reaching the cutoff of 20 years.
The expected length of transmission chains and the transmission
cluster size for each DRM, given there was at least one transmis-
sion event from the index case, are presented in Table 2, and shown
in Figures 2 and 3 (and S2 and S3 in the SI). Box-plots in Figures 2
and3(andFigures S2andS3intheSI)showthemedianandIQRsof
thesimulationswheretherewasatleastonetransmissioneventfrom
the index case. Whiskers on the box-plots indicate the largest and
Table 2 | Results from 110,000 simulations of the stochastic transmission chain model; 10,000 simulations were conducted for each DRM
andthewild-typestrain.Valuesoftherelativefitnesscostswereusedinthewithin-hostmodeltotrackviraldynamicswithineachindividualin
a transmission chain
DRM
Simulations where no
transmission occurred (%)
Expected Cluster Size
(if transmission occurs)
Expected Chain Length
(if transmission occurs)
Relative fitness cost used
in simulation (%)
Wild-type 18 76.4 7.82 22
K70R 20 63.0 7.51 0.17
Y181C 23 48.3 7.04 0.26
K219Q 47 6.55 3.05 0.60
L74V 58 3.70 1.97 0.86
D67N 75 2.59 1.37 1.6
M41L 80 2.42 1.28 1.9
K103N 86 2.27 1.18 2.6
T215Y 95 2.09 1.07 5.5
M184V 96 2.06 1.05 6.0
K65R 96 2.05 1.04 12
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1.5 times the IQR. Outliers beyond this are represented with open
circles. In Figure 2 (and Figure S2 in the SI) outliers are shown for the
chain lengths for the wild-type and 8 of the DRMs (K219Q, L74V,
D67N, M41L, K103N, T215Y, M184V and K65R), the remaining 2
DRMs (K70R and Y181C) do not have outliers. Note, transmission
cluster size is shown on a logarithmic scale in Figure 3 and S3 in the SI.
In our simulations, no transmission occurred from 20% of the
index cases infected with wild-type strains (Table 1). Furthermore,
when transmission did occur there was very wide variation in the
lengthoftransmissionchainsandtheirassociatedtransmissionclus-
ters that were generated by an index case (Figures 2 and 3). When
transmission did occur from an index case infected with wild-type
strains, transmission chains could last for ,8 (mean) generations
and generate transmission clusters of ,76 (mean) infected indivi-
duals (Table2, Figures 2 and 3). In atransmission cluster of this size,
,2 individuals would be directly infected by the index case and ,74
would be indirectly infected in the second, third and subsequent
generations.
As we found for wild-type strains, no transmission occurred from
,20% of the index cases infected with strains with DRMs that have
verylowfitnesscostsandR0’saboveone(K70RorY181C)(Table2).
If these DRMs were transmitted there was very wide variation in the
length of their transmission chains and the size of the associated
transmission clusters (Figures 2 and 3). Transmission of K70R (the
most fit of the 10 DRMs) was fairly similar to wild-type, but with
slightly smaller transmission clusters of ,63 (mean) infected indi-
viduals (Table 2, Figures 2 and 3). Transmission of Y181C was
noticeably lower than wild-type and generated significantly smaller
transmission clusters of ,48 (mean) infected individuals (Table 2,
Figures 2 and 3).
Transmission of DRMs with moderate fitness costs and R0’s just
belowone(K219QandL74V)wassignificantlylowerthanwild-type
strains (Table 2, Figures 2 and 3). Only ,40-50% of the index cases
infected with these DRMs transmitted them (Table 2). Furthermore,
whentransmissionoccurred,chainsweremuchshorter(2–3genera-
tions, mean values) and transmission clusters were much smaller
(,4–7 infected individuals, mean values) than for wild-type strains
(Table 2, Figures 2 and 3).
Transmission of DRMs with high fitness costs and R0’s much
lower than one (D67N, M41L and K103N) was substantially lower
thanwild-typestrains (Table2,Figures 2and3,Figures S2andS3in
SI). In this case only 14–25% of index cases transmitted DRMs.
When transmission occurred, the index case generally only trans-
mittedtheDRMtothenextgenerationandthentherewasnofurther
transmission; hence transmission chains only lasted for ,1 genera-
tionand transmission clusters were small, ,2–3infected individuals
(Table 2, Figures 2 and 3, Figures S2 and S3 in SI). However, due to
stochastic factors, longer transmission chains and larger transmis-
sion clusters sometimes occurred (Figures 2 and 3, Figures S2 and S3
in SI). For example, one index case transmitted M41L for 7 genera-
tions and generated a transmission cluster of 9 infected individuals
(Figures 2 and 3).
Our results show transmission of DRMs with very high fitness
costs and R0’s close to zero (T215Y, M184V and K65R) are unlikely
to betransmitted; only 4%–5% of index cases that were infected with
these DRMs transmitted them (Table 2, Figures S2 and S3 in SI).
When transmission occurred, as for DRMs with high fitness costs,
the transmission chains generally only lasted for ,1 generation and
transmission clusters were small, ,2 infected individuals (Table 2,
Figures S2 and S3 in SI). Due to stochastic factors, these DRMs were
occasionally transmitted for 3 generations and generated transmis-
sion clusters of 4–5 infected individuals (Figures S2 and S3 in SI).
Figure 2 | BoxplotsshowingdistributionsofthelengthoftransmissionchainsfortwoDRMswithlowfitnesscosts(K70Rwithafitnesscostof0.17%;
Y181C with a fitness cost of 0.26%), two DRMs with moderate fitness costs (K219Q with a fitness cost of 0.6%; L74V with a fitness cost of 0.86%), two
DRMs with high fitness costs (D67N with a fitness cost of 1.6%; M41L with a fitness cost of 1.9%) and the wild-type strain. Each box plot is based on
10,000 simulations of the stochastic model. Only simulations for which there is at least one transmission of the DRM from the index case are plotted.
Medians are denoted by solidblack lines whilethe topand bottom box edges denotethe first and third quartile. Whiskers denote the largest andsmallest
data within 1.5 times the interquartile range.
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DRMs. We tracked chronological time during our stochastic
simulations in order to visualize the temporal patterns in the
development of a transmission chain for both wild-type strains
and strains with a DRM. In the majority of cases strains with
DRMs that had high (D67N, M41L and K103N) or very high
(T215Y, M184V and K65R) fitness costs quickly went extinct (see
Table 1). When they were transmitted they showed almost no
diversity in the pattern of their transmission chain, as transmission
chains were short andcluster sizes were small. However, strains with
DRMs with low (K70R and Y181C) fitness costs, moderate (K219Q
and L74V) fitness costs and the wild-type strain showed a wide
diversity of patterns during the development of their transmission
chains and associated transmission clusters.
This diversity is illustrated in Figure 4; as an example the DRM
K219Q is shown. Each pattern is the result of one stochastic simu-
lation and shows the number of new infections, with K219Q, which
occurred each year (over a maximum of 20 years) during the
development of one transmission chain. The red block represents
the index case and each blue block represents a new infection with
K219Q.Horizontalblacklinesrepresenttheyearsinwhichtherewas
either no transmission of either K219Q (or the wild-type strain) or
only the wild-type strain was transmitted; transmission of the wild-
type strain is not shown. The four transmission chains for K219Q
differ in length, the size of the transmission cluster and their trans-
mission pattern (i.e., their development). Chain length varies from a
minimum of 9 generations (Figure 4a) to a maximum of 13 genera-
tions (Figure 4b), and cluster size varies from a minimum of 18
(Figure 4a) to a maximum of 81 (Figure 4b). In Figure 4A the chain
develops fairly slowly and then increases to 2 or 3 infections per year
before all transmission of K219Q terminates at ,15 years. In
Figure4bthechainforK219Qevolvesinacomplexmanner;initially
transmission is fairly high, but after a few years it begins to alternate
betweenperiodsofhighandlowtransmission.InFigure4ctheindex
case does not transmit K219Q until several years after infection;
transmission remains fairly steady for a few years and then increases
to form a large cluster. In Figure 4d transmission of K219Q remains
low and fairly constant for 20 years.
Our stochastic model, as well as tracking the length of a transmis-
sion chain, the associated cluster size and the transmission pattern
Figure 3 | Box plots showing distributions of the transmission cluster size for two DRMs with low fitness costs (K70R with a fitness cost of 0.17%;
Y181C with a fitness cost of 0.26%), two DRMs with moderate fitness costs (K219Q with a fitness cost of 0.6%; L74V with a fitness cost of 0.86%), and
two DRMs with high fitness costs (D67N with a fitness cost of 1.6%; M41L with a fitness cost of 1.9%) and the wild-type strain. Box plots showing
distributions of the transmission cluster size for two DRMs with moderate fitness costs. Each box plot is based on 10,000 simulations of the stochastic
model.OnlysimulationsforwhichthereisatleastonetransmissionoftheDRMfromtheindexcaseareplotted.Mediansaredenotedbysolidblacklines
while the top and bottom box edges denote the first and third quartile. Whiskers denote the largest and smallest data within 1.5 times the interquartile
range. Note the logarithmic scale.
Figure 4 | Figures (a), (b), (c) and (d) show temporal patterns for four
transmission chains of K219Q which were generated using the stochastic
model. Each chain is tracked over 20 years beginning with the index case.
Red blocks represent index cases and each blue block represents one new
infectionwithaDRM.Yearsinwhichnoinfections occuraredenoted by a
horizontal black line.
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several definitions in the literature. In previous modeling studies,
networkshavebeenspecifiedandthenusedasinputstoamathemat-
ical model; these networks have been defined based on sexual/social
behaviors. Whereas in empirical molecular epidemiological studies,
networks are determined from the empirical data that are collected;
these networks are defined based on the specific transmission events
that have occurred. Consequently, the observed transmission net-
workisasubsetofabehavioralnetwork.Anovelfeatureofourmodel
isitgenerates atransmission network, andnotabehavioralnetwork.
Each transmission chain generates its own transmission network.
The structure of the network shows which HIV-infected individual
has transmitted HIV to which susceptible individual over a specified
window of time. Hence the network represents a directed tree.
Network structure reflects a cross-section of the transmission chain
over a specified period of time. Consequently network structure,
as in molecular epidemiological studies, depends on the length of
the window period. The transmission networks we generate are
constrained by the unspecified underlying behavioral networks.
Therefore it is possible that the length of transmission chains and
the size of transmission clusters that we have calculated represent
upperbounds as to thatwhich may be observed from empirical data.
InFigure5weshowthenetworkstructure,basedonthenumberof
transmission events that occurred over a time period of 10 years, for
each of the 4 transmission chains of K219Q shown in Figure 4. Only
the events in which the DRM was transmitted are shown. As can be
seen, very different network structures can develop (Figure 5).
Similar results were found for the other DRMs with moderate
(L74V) and low (K70R and Y181C) fitness costs and the wild-type
strain (results not shown).
Discussion
Usingournovelstochasticmodel,andempiricaldata,wehavegained
important new insights into the transmission of wild-type strains.
Notably,wehavefoundasignificantproportionofindexcases(20%)
infected with wild-type strains, although they have sex with uninfec-
ted partners, may not transmit HIV. Our results suggest stochastic
factors that influence sexual transmission in a MSM community
could have fairly substantial effects on limiting transmission of
wild-typestrains.Thisoccursbecausetheprobabilityoftransmission
of HIV during any single sex act is low (0.001–0.003). We have
found that if transmission does occur, the length of the resulting
transmission chain is likely to be fairly long and the number of
infected individuals in a transmission cluster to be fairly high.
Notably,ourresultsareinagreementwithrecentresultsfromastudy
of wild-type strains ina community of MSM; this study identified 38
transmission clusters with a mean cluster size of 29 and a maximum
clustersizeof263
24.Wehavefoundwild-typestrainscanbeexpected
to show considerable variation in the length of their transmission
chainsandthesizeoftheirtransmissionclusters.Theseresultsimply
that molecular epidemiologic and phylogenetic studies are likely
to uncover a wide diversity of transmission patterns and network
structures.
We have also gained important new insights into the factors lim-
iting thetransmissionofDRMs. As with wild-type strains, theirtrans-
mission is influenced by stochastic factors
25. In addition, they are
limited by other factors. We have found the effects of reduced fitness
and genetic bottlenecks have a relatively minor impact on limiting
transmission of very fit DRMs (K70R and Y181C). Transmission of
these DRMs, because their fitness costs are low, is almost comparable
to wild-type; because they have a high probability of ‘‘surviving’’
multiplegeneticbottlenecks.DRMs with lowtomoderatefitnesscosts
(K70R, Y181C, K219Q and L74V) can be expected to show consid-
erable variation in the length of transmission chains and the size of
transmission clusters, as well as a high diversity in transmission pat-
terns and network structures. We have found that the higher the
fitness cost of a DRM, the lower the probability that it will ‘‘survive’’
many genetic bottlenecks; hence the shorter the transmission chains
and the smaller the associated transmission clusters. Reduced fitness
and genetic bottlenecks have a very substantial effect on limiting the
transmission of DRMs with high (D67N, M41L and K103N) or very
high fitness costs (T215Y, M184V and K65R). Our results are in
agreement with the limited empirical data; for example, we have
estimated the average cluster size for K103N to be ,2, and empirical
studies have identified clusters of this DRM consisting of only two
individuals
19. Notably, we have found DRMs with very high fitness
costs, between 6 to 12%, result in very infrequent transmission.
Our modeling shows that the transmission of DRMs with very
low fitness costs (K70R and Y181C) has the potential to reach
self-sustaining levels in certain communities as the value of their
Figure 5 | Networkstructure(overthelast10yearsofatransmissionchain)forthefourtransmissionpatternsforK219QshowninFigure4. Infections
with wild-type strains are not shown. Each of the 4 networks was generated by one index case.
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phylogenetic studies that have established the presence of self-sus-
taining drug resistant lineages circulating in treatment naı ¨ve indivi-
duals
26. However, if a DRM has a fitness cost greater than 0.4% its R0
is less than one; consequently transmission of this DRM is not high
enough to be self-sustaining. Notably, if a DRM (with an R0, 1)
evolves fairly frequently under the selective pressure of treatment it
could be highly prevalent. For example, M184V is rarely observed in
treatment-naı ¨ve individuals
19 but its prevalence is nearly 50% in
treatment-experienced individuals
27–29. Conversely, if a DRM with
an R0 greater than one only emerges infrequently under the selective
pressure of treatment it could have a low prevalence. Due to the
interaction between acquired resistance and transmitted resistance
in driving prevalence, the prevalence of individual DRMs that are
associated with resistance to non-nucleoside reverse transcriptase
inhibitors (NNRTIs) has been found to be very variable
29: 22% for
K70R, 13% forK219Q, 2.7% for L74V, 25% for D67N, 34% forT215Y,
33% for M41L, 51% for M184V, and 1.2% for K65R among NRTI
experienced individuals. The prevalence in treatment-experienced
individuals for the two DRMs associated with resistance to NNRTIs,
that we investigate, ranges from 22% for Y181C to 40% for K103N.
In this study we limited our analysis to investigating the effect of
fitness costs and genetic bottlenecks on limiting the transmission
ofDRMswhich resultfromsingle nucleotide mutations. Wefocused
on single mutants to first define how well-known fitness effects may
influence the dynamics of transmitting resistance. Interestingly, our
findings are generally in agreement with the limited in-vivo data on
lengthoftransmissionchainsandsizeoftransmissionclustersassoc-
iated with drug-resistant transmission
19,30,31. However, we caution
that the overall in-vivo fitness cost of resistance mutations may in
some instances be modulated by other mutations, as some results
fromin-vitrostudieshaverecentlysuggested
4.Infutureworkweplan
to investigate the effect of complex mutational patterns and fitness
modulations on the transmission of DRMs. We will also extend
our analyses to include DRMs which confer resistance to protease,
integrase, and fusion inhibitors. In addition, we will develop more
complex models that include behavioral networks and assess their
effect on constraining transmission networks. At that final stage
we will compare our predictions for transmission networks with
empirical network data obtained from well characterized cohorts
of primary HIV infections.
Using the current resistance assays, our results indicate transmit-
tedDRMs withlow fitness costs(K70R andY181C) arevery likely to
be detected in treatment-naive individuals, because these DRMs can
persist for 8 or more years. However, DRMs with moderate fitness
costs (K219Q and L74V) may not be detected if treatment-naı ¨ve
individuals are tested for resistance more than 3.5 years after the
transmission event. DRMs with high fitness costs (D67N, M41L
and K103N) are unlikely to be detected if resistance testing occurs
more than one year after the transmission event. Notably, we have
foundDRMswithveryhighfitnesscosts(T215Y,M184VandK65R)
will not be detected unless resistance testing takes place during, or
soon after, primary infection.
Ourresultsimplytherecouldbeahiddenepidemicoftransmitted
resistance composed of strains with DRMs that have moderate, high
or very high fitness costs. Although these DRMs may be present at
very low levels in individuals they are likely to reemerge under treat-
ment pressure and have clinical significance. A recent study has
shown that even when DRMs are present at very low levels
(0.003% to 2%) within an individual, well below the detection
level of current resistance assays, they more than double the risk of
virologic failure
3. Consequently, a hidden epidemic of transmitted
resistanceislikelytohavesignificantconsequences forpublichealth.
Our results have shown that introducing the next generation of
resistance assays, with sensitivities as low as 1%, is unlikely to
increase the detection of DRMs that have low fitness costs (K70R
and Y181C) since these DRMs can already be detected for 8 or more
years. However introducing these new assays could substantially
increase the detection of DRMs with moderate fitness costs
(K219Q and L74V) as their detection time will increase to ,3–5
years post-seroconversion. Notably, our results indicate the new
assays are unlikely to increase detection of DRMs with high
(D67N, M41L, and K103N) or very high (T215Y, M184V and
K65R) fitness costs because their detection times will only increase
by one to two months. Therefore, even after the introduction of the
next generation of more sensitive resistance assays, an epidemic of
transmitted resistance could remain partially hidden.
Methods
Defining Fitness Costs. Fitness cost of a DRMcan be expressed as either an absolute
fitness cost or a relative fitness cost. The absolute fitness cost of a DRM is the
difference in the replicationrate of a wild-type and a resistant strain; this is expressed
intermsofvirionsperunittime.TherelativefitnesscostofaDRMisthedifferencein
the replication rate between a wild-type and a resistant strain divided by the
replicationrateofthewild-typestrain;thiscanbeexpressedeitherasapercentageora
proportion.
Estimating Fitness Costs. To conduct our modeling analyses we needed to estimate
the relative fitness cost for 9 (Y181C, K103N, K70R, L74V, K219Q, M41L, D67N,
T215Y and K65R) of the 10 DRMs in our analysis. We note that that the relative
fitness cost of M184V is known, it has been estimated previously by Paredes et al.
16.
The absolute fitness cost can be converted into the relative fitness cost. Conversely,
the relative fitness cost can be converted into the absolute fitness cost. To make this
conversionitisnecessarytoknowthereplication rate
32.Wecalculated relative fitness
costs in two steps. In step one, we used estimates for absolute fitness costs from Cong
et al.
4 and the estimate of the relative fitness cost of M184V from Paredes et al.
16 as a
calibration factor to calculate the replication rate of the wild-type strain. In step two,
we divided estimates for the absolute fitness costs from Cong et al. by our calculated
replication rate of the wild-type strain.
Cong and colleagues estimated absolute fitness costs for each of the 10 DRMs by
conductingaseriesofviralcompetitionexperiments.Intheseexperimentseachstrain
with a DRM was compared, in terms of its replication rate, with the corresponding
isogenic wild-type strain
4. During experiments the proportion of virions that were
wild-type versus those which contained the DRM were tracked over a series of
passages (i.e., over time) in MT4-cell culture; several passages were used to prevent
significantdepletionofMT4cells.Asshownbytheirexperimentaldata
4thelogofthe
ratio of the number of virions with a DRM to the number of wild-type virions
decreases linearly over time. Standard mathematical growth-competition models, as
described in Maree et al.
32, predict that the relationship is:
log10
Mt ðÞ =M 0 ðÞ
Wt ðÞ =W 0 ðÞ

~{tRD ð1Þ
where M(t) represents the number of virions with a DRM per microliter of blood at
time t, W(t) the number of wild-type virions per microliter of blood at time t, R the
replicationrateofthewild-typestrainandDtherelativefitnesscost(duetotheDRM)
expressed as a proportion. Note that in equation 1 the product of R and D equals the
absolute fitness cost.
BydividingthevalueoftheabsolutefitnesscostforM184VestimatedbyCongetal.
by the relative fitness cost of M184V estimated by Paredes et al.
16 we calculated the
replication rate of the wild-type strain. We assumed this replication rate was
approximatelyconstantinallofthecompetitionexperimentsconductedbyCongand
colleagues, because MT4 concentrations were non-limiting.
We then, for each of the DRMs except M184V, estimated their relative fitness cost
by dividing the value of their absolute fitness cost (estimated by Cong et al.)b yo u r
calculated rate of replication of the wild-type strain. Due to the fact that Paredes et
al.
16, by using data from several patients, had calculated a range of estimates for the
relative fitness cost of M184V we calculated (for each DRM) a range for their relative
fitness cost. Estimates of the relative fitness costs of M184V, measured by Paredes et
al
16, ranged from 4% to 8%.
Estimating Detection Times. We used the estimated relative fitness costs for the
10 DRMsandapublishedwithin-hostmodelofviraldynamicstocalculatethelength
of time each DRM is likely to remain detectable in the plasma of a treatment-naı ¨ve
individual (i.e., their detection time)
13; see SI for a detailed description of the within-
hostmodelandparametervalues.Usingthemodel,wewereabletotrackthetemporal
dynamics of the total viral load within an individual. In addition, for individuals
infected with a strain with a DRM we were also able to calculate what percentage of
their virion population, at any point in time, was composed of strains with a DRM.
We simulated the within-hostmodel fora maximum of 8years because wesimulated
sexualtransmissioninMSMinresource-richcountries,andmostHIV-infectedMSM
in these countries are on treatment by that time
15. We calculated detection times
based on a detection threshold for resistance of 20% (which is the detection limit for
current resistance assays) and we also calculated detection times based on using next
generation resistance assays with a detection limit of 1%.
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analysis. For this analysis we varied the relative fitness cost (over the range shown in
Table 1), the viral clearance rate (from 10 to 30 day
21)
33, the set point viral load (from
20 to60 virions/mL
15,34,35) and the set point for CD4 cells (from 350 to 550 cells/mL
22,34).
For further discussion of parameter ranges see SI. The uncertainty analysis was based
on Latin Hypercube Sampling
36 and we used Monte Carlo Filtering to ensure the burst
size of the wild-type strain was always greater than 100 virions per cell.
Modeling the stochastic development of Transmission Chains. Our novel
stochastic transmission model is constructed to track the development of one trans-
mission chain and the associated transmission cluster. We begin each transmission
chain with an index case in the primary/acute stage of infection and infected with
either the wild-type strain or a strain with a DRM that can revert (over time) to wild-
type.WemodeltheprobabilityaninfectedindividualtransmitsHIV(eitherwild-type
or the strain with the DRM) at any point in time (pre-treatment) as a stochastic
process that is a function of viral load. Therefore we model sexual transmission as a
seriesofstochasticevents.Ageneticbottleneckoccursateachtransmissioneventand,
duetothefoundereffect,onlythewild-typeorthestrainwiththeDRMistransmitted.
Whether the founder virus is wild-type or has the DRM is determined
probabilistically, but depends upon the composition (at the time of transmission)
ofthevirionpopulationinthetransmittingindividual.Weusethewithin-hostmodel
to track the competitive-reversion dynamics between wild-type and a strain with a
DRM within each treatment-naı ¨ve individual in the transmission chain
13. We model
thereversionrateofeachoftheDRMsusingourestimatesoftherelativefitnesscosts.
The model is parameterized to reflect the current epidemiological and treatment
conditions in the MSM community in San Francisco. Current treatment guidelines
for HIV recommend treatment should begin when an individual’s CD4 count drops
below 350 cells/mL. However, there is considerable variation in as to when HIV-
infected individuals actually begin treatment; in resource-rich countries many indi-
viduals begin treatment before their CD4 counts fall to 350 cells/mL
15. Therefore,
when conducting our stochastic simulations, we modeled variation in time to treat-
ment.UsingCD4datafromSanFranciscodataandpublishedratesofCD4declinein
HIV-infected individuals
37,38, we calculated that HIV-infected individuals in San
Francisco generally begin treatment 6 to 8 years after infection
15. Consequently, for
each individual (in each stochastic simulation), we sampled from a range of 6 to 8
years to determine when they would begin treatment. For each individual, we then
used the within-host model to track their viral load over time. When the individual
began treatment, we set their viral load to effectively zero.
We conducted 10,000 simulations of transmission chains for each of the 10 DRMs
and the wild-type strain; each simulation tracked one transmission chain. Hence we
conducted a total of 110,000 simulations. Chains were tracked for a maximum of 20
years. We chose a cutoff of 20 years as this represents the approximate time of
introduction of antiretroviral therapy in resource-rich countries, when DRMs first
evolved. Chains terminated due to either stochastic effects or to reaching the time
point of 20 years. To identify the reason for termination of each of the transmission
chains, we calculated cumulative distribution functions for the proportion of (non-
null) chains that terminated in each year (See Figure S4 in the SI). We tracked each
chainthatdidnotterminatestochastically,beyondthe20yearcutofftoensurethatwe
correctly identified the terminal transmission event.
Estimating R0. We used the value of R0 for wild-type strains of HIV to estimate the
valuesofR0forthe strainswithDRMs(seeSI).TheR0forthewild-typestrainwasset
at1.6,asthisisthevalueofR0thathasrecentlybeenestimatedforwild-typestrainsof
HIV (in the presence of treatment programs) in the community of MSM in San
Francisco
34. To estimate R0 for each of the DRM we used the 100,000 simulations of
transmission chains. For each simulation, we determined the number of infections
with a DRM in the second generation of the chain (i.e., R0). We conducted an
uncertaintyanalysisontheR0foreachDRM.Theuncertaintyanalysiswasconducted
using the same parameter set for the within-host model as employed in the
uncertaintyanalysisofthedetectiontimes.WethencomputedthemedianvalueofR0
and the interquartile range over all simulations.
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